Seaview Investment Managers LLC Sells 59,091 Shares of Abbott Laboratories $ABT

Key Points

• Seaview Investment Managers LLC cut its Abbott Laboratories stake by 97.3% in the fourth quarter, selling 59,091 shares and leaving it with 1,668 shares valued at about $209,000.
• Abbott still has strong institutional backing, with hedge funds and other institutional investors owning 75.18% of the company’s stock, while several major firms such as Vanguard and Capital International Investors added to positions.
• Analysts remain cautiously positive despite recent target-price cuts: Abbott has a consensus rating of “Moderate Buy,” and the company beat Q1 earnings and revenue estimates while issuing FY2026 guidance of $5.38–$5.58 EPS.

Seaview Investment Managers LLC trimmed its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 97.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,668 shares of the healthcare product maker's stock after selling 59,091 shares during the period. Seaview Investment Managers LLC's holdings in Abbott Laboratories were worth $209,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. Capital International Investors boosted its position in Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Invesco Ltd. grew its stake in Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Abbott Laboratories by 3.8% during the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker's stock valued at $1,804,050,000 after acquiring an additional 499,351 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Abbott Laboratories by 7.2% during the third quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker's stock valued at $1,727,869,000 after purchasing an additional 864,531 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insiders Place Their Bets

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business's stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ABT has been the subject of a number of recent research reports. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating on the stock in a research report on Tuesday, April 21st. Benchmark reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. UBS Group reduced their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research report on Monday, April 20th. Finally, Barclays reduced their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $119.43.

Abbott Laboratories Stock Up 0.0%

NYSE ABT opened at $87.42 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market capitalization of $152.27 billion, a P/E ratio of 24.49, a P/E/G ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The stock has a 50 day moving average price of $96.32 and a 200-day moving average price of $111.70.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.